# Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)

> **NCT02140606** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.**

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Cafusertib Hydrochloride

## Key facts

- **NCT ID:** NCT02140606
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2015-12
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140606, "Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02140606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*